

**GOVERNMENT OF INDIA
MINISTRY OF CORPORATE AFFAIRS**

**LOK SABHA
UNSTARRED QUESTION NO. 1450
ANSWERED ON MONDAY THE 1ST JULY, 2019
{ASHADHA 10, 1941 (SAKA)}**

MONITOR ACTIVITIES AGAINST PHARMA COMPANIES

QUESTION

1450. PROF. SAUGATA ROY:

**Will the Minister of CORPORATE AFFAIRS
be pleased to state:**

कारपोरेट कार्य मंत्री

- (a) whether the Competition Commission of India has any mechanism to monitor the un-ethic practices of business by various pharma companies of the country;
- (b) if so, the details thereof; and
- (c) the details of penalties imposed by CCI during the last three years on Pharma companies in the country?

ANSWER

**THE MINISTER FOR FINANCE AND
CORPORATE AFFAIRS**

(SMT. NIRMALA SITHARAMAN)

वित्त एवं कारपोरेट कार्य मंत्री

(श्रीमती निर्मला सीतारामन)

(a) & (b): Unethical practices do not come under the purview of CCI. However, under the provisions of Section 3 and 4 of the Competition Act, 2002, the Competition Commission of India (CCI) is, *inter alia*, mandated to prevent practices having adverse effect on competition. The CCI inquires into allegation of anti-competitive agreements and abuse of dominant position, including with respect to the conduct of pharma companies, on its own motion or on receipt of an information/reference under Section 19 of the Act.

(c): The details of penalties imposed by CCI on pharma companies during the last three years are as under:-

Financial Year	Penalty Imposed (in Rs. Lakhs)
2016-17	7296.00
2017-18	0.00
2018-19	4643.26
